PEAK6’s Definium Therapeutics DFTX Stock Holding History

PEAK6’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$423K	Buy	+9,000	New	+$222K	﹤0.01%	2037

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PEAK6's DFTX Position: Q3 2025 in Review

PEAK6 sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 10,915 shares — an estimated $102K sold.

PEAK6 first reported a position in DFTX in Q4 2024 and held it in 3 quarters. The position peaked at $76.1K in Q1 2025. 196 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

PEAK6 reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 10,915 Definium Therapeutics shares in Q3 2025, an estimated $102K.
PEAK6 first reported a position in Definium Therapeutics in Q4 2024 and held it in 3 quarters.
PEAK6's Definium Therapeutics position peaked at $76.1K in Q1 2025.
196 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.